Cadila Healthcare Q4 Review - India Sales, Operating Leverage Drives Earnings: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Cadila Healthcare Ltd. delivered in line Q4 FY21 earnings.
Healthy traction in the domestic formulation and consumer wellness has offset the impact of weak U.S. sales and improved Ebitda margin.
It is well-placed to benefit from preventive as well as treatment drugs for Covid-19, in addition to improving performance in its core domestic formulation portfolio.
The innovative pipeline is also progressing well in clinical studies.
We remain positive on the company on account of:
superior execution in the DF segment,
favourable demand for Covid-19 products,
innovative as well as a complex generic pipeline (including injectables and transdermals), and
reducing financial leverage.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.